Commonwealth Fund July 30, 2021
Kristi Martin

Toplines

President Biden signed an executive order to promote competition in prescription drug markets — a move aimed at lowering drug costs

The order lays out actions for federal agencies to address anticompetitive behaviors of drug manufacturers and explore tactics to increase the use of generic drugs and biosimilars

Earlier this month, President Biden signed an executive order, Promoting Competition in the American Economy. The order lays out actions to address consolidation in health care markets and price competition in the prescription drug markets. The administration has indicated that lowering drug prices is a priority and instructed agencies to act. In addition, Congress is working to move drug pricing reform this year. A comprehensive approach is needed that focuses on...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Healthcare System, Pharma, Pharma / Biotech, Pricing / Spending
Congress Must Act To Advance Innovation In Medicaid
Physician-led ACOs are the most effective at reducing care costs: report
Patient advocates shred Becerra's copay accumulator comments
Opinion: Former HHS secretaries: Congress should adopt site-neutral payments for health care
One Year into the Biden Administration's Care Executive Order

Share This Article